By the conclusion of the trans-Atlantic slave trade at the end of the 19th century, Europeans had enslaved and transported more than 12.5 million Africans.

Three years after Daiichi Sankyo's FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US ...